Stocks Movement Analysis: Marathon Oil Corporation (NYSE:MRO), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)



Marathon Oil Corporation (NYSE:MRO)

Marathon Oil Corporation is a leading exploration and production company with extensive operations across four core regions – Africa, Middle East, Europe and North America. As of year-end 2014, Marathon had approximately 2.2 billion oil-equivalent barrels (BBOE) in proved reserves (80% liquids and 67% developed). The company’s business is organized into three segments – North America Exploration and Production, International Exploration and Production, and Oil Sands Mining. In July 2011, Marathon completed the spin-off of its refining/sales business into a separate, independent and publicly traded company Marathon Petroleum Corporation (Ticker: MPC).

Marathon Oil Corporation (NYSE:MRO)’s Financial Overview

Marathon Oil Corporation (NYSE:MRO) surged 20.8% yesterday to close its trading session at $18.06. The company has 1 year Price Target of $18.12. Marathon Oil Corporation has 52-Week high of $18.55 and 52-Week Low of $6.52. The stock touched its 52-Week High on Nov 30, 2016 and 52-Week Low on Feb 19, 2016. The stock traded with the volume of 74.55 Million shares yesterday. The firm shows the market capitalization of $15.3 Billion.

Marathon Oil Corporation (NYSE:MRO) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $-0.11/share against the analyst consensus estimate of $-0.2/share. The difference between the actual and expected EPS is $0.09 a share with a surprise factor of 45%.

The firm is trading with SMA20 of 20.15 Percent, SMA50 of 21.52 Percent and SMA200 of 34.22 percent. Marathon Oil Corporation has P/S value of 3.62 while its P/B value stands at 0.81. Similarly, the company has Return on Assets of -4.8 percent, Return on Equity of -8.2 percent and Return on Investment of -7.5 Percent. The company shows Gross Margin and Operating Margin of 60 percent and -44.2 percent respectively.

Many brokerage firms are involved in issuing their ratings on Marathon Oil Corporation (NYSE:MRO). On 18-Nov-16 Susquehanna Initiated Marathon Oil Corporation Stock  to Neutral. Another firm also rated the stock on 17-Oct-16 where Barclays Downgrade the stock to Equal Weight.

The Stock currently has Analyst’ mean Recommendation of 2.5 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 28 analysts offering 12-month price forecasts for Marathon Oil have a median target of 17.00, with a high estimate of 25.00 and a low estimate of 10.00. The median estimate represents a -5.87% decrease from the last price of 18.06.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +663.89% increase from the last price of 1.44.

Arrowhead Pharmaceuticals, Inc. is estimated to report earnings on  12/12/2016. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.33.  The reported EPS for the same quarter last year was $-0.42.

According to Zacks Investment Research, Arrowhead Pharmaceuticals, Inc. has a Consensus Recommendation of 1.4. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -67.2% and closed its last trading session at $1.44. The company has the market capitalization of $87.49 Million. The stock has 52-week high of $8.22 and 52-Week low of $1.42. The firm touched its 52-Week high on Aug 24, 2016 and 52-Week low on Nov 30, 2016. The company has volume of 18.1 Million shares. The company has a total of 60.76 Million shares outstanding.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the last quarter reported its actual EPS of $-0.32/share where the analyst estimated EPS was $-0.37/share. The difference between the actual and Estimated EPS is $0.05. This shows a surprise factor of 13.5 percent.

The company has YTD performance of -76.59 percent. Beta for Arrowhead Pharmaceuticals, Inc. stands at 2.31 while its ATR (average true range) is 0.52. The company has Weekly Volatility of 9.90%% and Monthly Volatility of 8.52%%.

Arrowhead Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -70.34%, Distance from 50-Day Simple Moving Average of -76.23 percent and Distance from 200-Day Simple Moving Average of -75%.

The Company currently has ROA (Return on Assets) of -79.5 percent, Return on Equity (ROE) of -99.8 Percent and Return on Investment (ROI) of -86.5% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.